Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.07 -0.14 (-0.54%)

Streaming Delayed Price Updated: 1:27 PM EDT, Jun 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pfizer Stock Edges Lower Monday: What's Going On? ↗

Today 10:35 EDT

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.

Via Benzinga

GEA Group Aktiengesellschaft Targets EUR 7B Revenue, Higher Margins by 2030 ↗

Today 10:02 EDT

GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying...

Via MarketBeat

Topics Supply Chain

Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead ↗

Today 8:18 EDT

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Via The Motley Fool

Topics Artificial Intelligence Earnings Intellectual Property

GLP-1 Receptor Agonist Market Revenue Analysis Across Key Regions ↗

Today 7:04 EDT

The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion

Via Talk Markets

2 Reasons to Like ZTS and 1 to Stay Skeptical

Today 0:04 EDT

Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...

Via StockStory

Could Pfizer Stock Be Your Ticket to Generational Wealth? ↗

June 21, 2026

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Via The Motley Fool

Topics Intellectual Property

Want to Retire on $500,000? 3 Stocks to Buy and Never Sell ↗

June 21, 2026

These dividend stocks could help make retiring on $500,000 a real possibility.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors? ↗

June 20, 2026

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Via The Motley Fool

Topics Intellectual Property

Apple's Price Warning Sends Memory Chips To A Record, Accenture Cracks 18% ↗

June 19, 2026

Via Chartmill

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook ↗

June 18, 2026

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Via The Motley Fool

Topics Intellectual Property Stocks

Thursday's session: most active stock in the S&P500 index ↗

June 18, 2026

Via Chartmill

These S&P500 stocks have an unusual volume in today's session ↗

June 18, 2026

Via Chartmill

Pfizer Stock Drops Today As CFO Steps Down In August ↗

June 18, 2026

Pfizer shares are slipping Thursday after it announced that Chief Financial Officer Dave Denton will leave the organization.

Via Benzinga

3 S&P 500 Stocks Worth Your Attention

June 17, 2026

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...

Via StockStory

Topics Stocks

How to Build a Retirement Income Plan That Lasts Through a High-Inflation Decade ↗

June 16, 2026

If you haven't planned for inflation, and possibly high inflation, your nest egg's purchasing power could shrink alarmingly.

Via The Motley Fool

Topics Bonds ETFs Economy

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

June 16, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack

June 15, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...

Via StockStory

Topics Artificial Intelligence

Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth ↗

June 15, 2026

Pfizer's business may be in better shape than investors think.

Via The Motley Fool

Topics Earnings Intellectual Property

Have S&P 500 Index Funds, Often Touted as the Best Stock Investments, Become Dangerous? There's a Worrisome Development -- and a Possibly Better Alternative. ↗

June 14, 2026

The hard-earned dollars you park in a standard S&P 500 index fund may not be distributed the way you think they are.

Via The Motley Fool

Topics ETFs Stocks

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗

June 13, 2026

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

Via The Motley Fool

Topics Bonds Intellectual Property

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗

June 12, 2026

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Via The Motley Fool

Thursday's session: most active stock in the S&P500 index ↗

June 11, 2026

Via Chartmill

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗

June 11, 2026

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Via MarketBeat

Topics Intellectual Property

Why Pfizer Stock Popped Today ↗

June 11, 2026

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Via The Motley Fool

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗

June 11, 2026

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.

Via The Motley Fool

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗

June 09, 2026

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics...

Via MarketBeat

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗

June 09, 2026

Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate...

Via MarketBeat

2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 We Brush Off

June 09, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study ↗

June 08, 2026

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

Via Benzinga

Curious about the most active S&P500 stocks in today's session? ↗

June 08, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.